Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolving strategies in the initial treatment of multiple myeloma.
Rosenbaum C, Jasielec J, Laubach J, Paba Prada C, Richardson P, Jakubowiak AJ. Rosenbaum C, et al. Among authors: paba prada c. Semin Oncol. 2013 Oct;40(5):592-601. doi: 10.1053/j.seminoncol.2013.08.002. Semin Oncol. 2013. PMID: 24135404 Review.
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, Varga C, Mitsiades CS, Paba-Prada C, Schlossman R, Munshi N, Anderson KC, Richardson PP, Weller E, Ghobrial IM. Weinstock M, et al. Among authors: paba prada c. Br J Haematol. 2015 Jun;169(6):851-8. doi: 10.1111/bjh.13383. Epub 2015 Apr 1. Br J Haematol. 2015. PMID: 25833301 Free PMC article.
Treatment of Relapsed/Refractory Multiple Myeloma.
Neri P, Bahlis NJ, Paba-Prada C, Richardson P. Neri P, et al. Among authors: paba prada c. Cancer Treat Res. 2016;169:169-194. doi: 10.1007/978-3-319-40320-5_10. Cancer Treat Res. 2016. PMID: 27696263 Review.
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS. O'Donnell EK, et al. Among authors: paba prada ce. Br J Haematol. 2018 Jul;182(2):222-230. doi: 10.1111/bjh.15261. Epub 2018 May 8. Br J Haematol. 2018. PMID: 29740809 Free PMC article. Clinical Trial.
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG. Varga C, et al. Among authors: paba prada c. Br J Haematol. 2015 Jun;169(6):843-50. doi: 10.1111/bjh.13382. Br J Haematol. 2015. PMID: 26032514 Free article.
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG. Ghobrial IM, et al. Among authors: paba prada c. Am J Hematol. 2019 Nov;94(11):1244-1253. doi: 10.1002/ajh.25627. Epub 2019 Oct 4. Am J Hematol. 2019. PMID: 31456261 Free article. Clinical Trial.
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Rowinsky EK, Paner A, Berdeja JG, Paba-Prada C, Venugopal P, Porkka K, Gullbo J, Linder S, Loskog A, Richardson PG, Landgren O. Rowinsky EK, et al. Among authors: paba prada c. Invest New Drugs. 2020 Oct;38(5):1448-1453. doi: 10.1007/s10637-020-00915-4. Epub 2020 Mar 3. Invest New Drugs. 2020. PMID: 32125598 Free PMC article. Clinical Trial.
19 results